Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Lymphoma, B-Cell 2Colorectal Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Platinum-resistant Ovarian Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoplasm Metastasis 1Microsatellite Instability 1Melanoma 1Lung Neoplasms 1Liposarcoma, Myxoid 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 12fludarabine phosphate 7fludarabine 7venetoclax 6blinatumomab 6Cytarabine 5Lenalidomide 4Dexamethasone 4Blood Specimen Collection 4Azacitidine 4obinutuzumab 3Rituximab 3Radiotherapy 3Melphalan 3Immunotherapy, Adoptive 3pembrolizumab 2daratumumab 2Neoadjuvant Therapy 2Idarubicin 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1tislelizumab 1tisagenlecleucel 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sacituzumab govitecan 1sabatolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × ALT-803 × 1 year × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡